Registry of Pregnant women with IBD and their offspring to determine if IBD medications affects pregnancy and health of the baby.

• 1115 women (of which 896 delivered) were followed
• Patients on different medications (biologics, immunosuppressants) were studied and compared to unmedicated

Key findings-

IBD medication exposure during pregnancy was not associated with abnormalities in:

• Rate of congenital anomalies
• Infant height and weight
• Overall rates of infections
• Developmental milestones at months 4,9,12

Of the patients studied, those on biologics alone had a slightly increased rate of

• Spontaneous abortions
• C-sections

**These results may relate to the fact that patients with more severe disease took biologic therapies

Of the patients studied, those on combination therapy (Biologics and immunosuppressants) had a slightly increased rate of-

• Preterm birth
• Infections at 12 months
  • UC: Any complication, premature delivery, low birth weight, neonatal intensive care unit

**Again, these results may be due to the aggressive disease that led to combination drug use rather than the agents themselves